{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:33:11Z","timestamp":1778002391668,"version":"3.51.4"},"reference-count":67,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>\n            The treatment of CLL has evolved from traditional chemoimmunotherapy (CIT) to an increasing number of targeted and biologic approaches. Randomized trials have demonstrated superiority of covalent bruton tyrosine kinase inhibitors (cBTKis) over CIT, and second-generation compounds such as acalabrutinib and zanubrutinib appear to have a more favorable efficacy\/safety profile than ibrutinib. The noncovalent BTKi, pirtobrutinib, has shown impressive activity after failure of the cBTKis and is quite tolerable. The\n            <jats:italic>Bcl-2<\/jats:italic>\n            inhibitor venetoclax plus a CD20, generally obinutuzumab, provides a high level of efficacy as initial treatment or after failure on a cBTKi, with many patients achieving a state of undetectable minimal residual disease. Promising novel approaches include BTK degraders, bispecific antibodies, and chimeric antigen receptor T-cell (CAR-T)-cell therapy. What is clear is that CIT is archaic, and current and future targeted approaches will continue to improve the outcome for patients with chronic lymphocytic leukemia.\n          <\/jats:p>","DOI":"10.1200\/op.23.00770","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T20:01:25Z","timestamp":1717790485000},"page":"1360-1366","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":5,"title":["Current Approaches and Novel Agents in the Treatment of Chronic Lymphocytic Leukemia"],"prefix":"10.1200","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-7655","authenticated-orcid":true,"given":"Bruce D.","family":"Cheson","sequence":"first","affiliation":[{"name":"Center for Cancer and Blood Disorders, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[{"name":"Willamette Valley Cancer Institute, Medical Director of Hematology Research: Sara Cannon, Eugene, OR"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.7.1422.1422"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.5.868"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020158"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30212-1"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174750"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00884-4"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174289"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.259432"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830290307"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.7.1414.1414"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010845"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014616"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.272500"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00320-9"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879429"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013208"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30433-6"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000711"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V29.4.566.566"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018882555"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6840"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967492.06443.0a"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2809"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.32"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900574"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1649"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00894"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00807"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187128"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02283"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213093"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173709"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.7500"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000969472.42363.47"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0055"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169662"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300696"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185852"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0670"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114110"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01052-8"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158298"},{"key":"e_1_3_4_62_2","first-page":"abstract 154617","article-title":"Epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia: Results from the phase 1b\/2 EPCOR CLL-1 trial expansion cohort","author":"Kater AP","year":"2023","unstructured":"Kater AP, Eradat H, Niemann CU, et al: Epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia: Results from the phase 1b\/2 EPCOR CLL-1 trial expansion cohort. Proc IWCLL abstract 1546171, 2023","journal-title":"Proc IWCLL"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164772"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180109"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014760"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7556"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00598-x"},{"key":"e_1_3_4_68_2","article-title":"NVG-111, a novel ROR1xCD3 bispecific dantibody for non-Hodgkin lymphoma","volume":"39","author":"Granger D","year":"2023","unstructured":"Granger D, Gohil S, Barbarulo A, et al: NVG-111, a novel ROR1xCD3 bispecific dantibody for non-Hodgkin lymphoma. J Clin Oncol 39, 2023 (15_suppl; abstr 7549)","journal-title":"J Clin Oncol"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP.23.00770","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T20:36:25Z","timestamp":1730147785000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP.23.00770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1200\/OP.23.00770"],"URL":"https:\/\/doi.org\/10.1200\/op.23.00770","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2023-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}